xcourtney3 Posted April 16, 2011 Share Posted April 16, 2011 I'm going to the pdoc to get taken off of Zyprexa. I need some suggestions for a replacement antipsychotic. Preferably something weight neutral or at least something that won't put on as much weight as Zyprexa. Link to comment Share on other sites More sharing options...
SashaSue Posted April 16, 2011 Share Posted April 16, 2011 It's really hard to predict which AAP's will cause weight gain for any given person. You kind of have to just try them out and see how it goes, unfortunately. Link to comment Share on other sites More sharing options...
rowen Posted April 16, 2011 Share Posted April 16, 2011 Abilify and Geodon are supposedly weight neutral. Me and my gut disagree, however. Like Sasha said, you're not going to know until you try. My mom was a size 5 on Zyprexa. That's how varied things can be. Link to comment Share on other sites More sharing options...
netsavy006 Posted April 20, 2011 Share Posted April 20, 2011 From what I know, though everyone is different, as rowen had mentioned, Abilify and Geodon are proposed to be weight neutral. Link to comment Share on other sites More sharing options...
klingon001 Posted April 21, 2011 Share Posted April 21, 2011 ... Link to comment Share on other sites More sharing options...
netsavy006 Posted April 21, 2011 Share Posted April 21, 2011 According to the PI sheet for Saprhis, the rate of weight gain greater than 7% body weight was 5.8%. From PI Sheet: Increases in weight have been observed in pre-marketing clinical trials with SAPHRIS. Patients receiving SAPHRIS should receive regular monitoring of weight [see Patient Counseling Information (17.5)]. In short-term schizophrenia and bipolar mania trials, there were differences in mean weight gain between SAPHRIS-treated and placebo-treated patients. In short-term, placebo-controlled schizophrenia trials, the mean weight gain was 1.1 kg for SAPHRIS-treated patients compared to 0.1 kg for placebotreated patients. The proportion of patients with a ≥7% increase in body weight (at Endpoint) was 4.9% for SAPHRIS-treated patients versus 2% for placebo-treated patients. In short-term, placebo-controlled bipolar mania trials, the mean weight gain for SAPHRIS-treated patients was 1.3 kg compared to 0.2 kg for placebo-treated patients. The proportion of patients with a ≥7% increase in body weight (at Endpoint) was 5.8% for SAPHRIS-treated patients versus 0.5% for placebo-treated patients. Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.